» Articles » PMID: 24352218

Macrovascular Involvement in a Child with Atypical Hemolytic Uremic Syndrome

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2013 Dec 20
PMID 24352218
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a disorder of the complement system which leads to thrombotic microangiopathy. It is caused by either acquired or hereditary defects in the activation or regulation of the alternative complement pathway and is therefore considered to be a disease of local complement dysregulation in microvasculature with predominantly renal involvement. However, extrarenal manifestations are observed in approximately one-fifth of aHUS patients, with the myocardium and central nervous system (CNS) being involved most often. Additionally, there have been a few reports of aHUS with cerebral artery stenoses or periphereal gangrene, suggesting the possibility of 'macrovascular' involvement in aHUS.

Case-diagnosis/treatment: We present a child with early onset aHUS and a C3 gain-of-function mutation who developed cerebral artery stenoses, leading ultimately to death due to a massive stroke 9 days after successful renal transplantation under prophylactic eculizumab treatment. Similar cases described in the literature are also briefly summarized.

Conclusions: The disease course in our patient with aHUS confirms that dysregulated complement activation can induce arterial steno-occlusive lesions in the absence of acute episodes of HUS. Further studies are required to document the frequency of such macrovascular complications and the role of eculizumab treatment in preventing their development and progression.

Citing Articles

Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management.

Yerigeri K, Kadatane S, Mongan K, Boyer O, Burke L, Sethi S J Multidiscip Healthc. 2023; 16:2233-2249.

PMID: 37560408 PMC: 10408684. DOI: 10.2147/JMDH.S245620.


Identification of discriminative gene-level and protein-level features associated with pathogenic gain-of-function and loss-of-function variants.

Sevim Bayrak C, Stein D, Jain A, Chaudhary K, Nadkarni G, Van Vleck T Am J Hum Genet. 2021; 108(12):2301-2318.

PMID: 34762822 PMC: 8715146. DOI: 10.1016/j.ajhg.2021.10.007.


Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.

Cassol C, Williams M, Caza T, Rodriguez S Medicine (Baltimore). 2019; 98(39):e17148.

PMID: 31574818 PMC: 6775360. DOI: 10.1097/MD.0000000000017148.


Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Socie G, Caby-Tosi M, Marantz J, Cole A, Bedrosian C, Gasteyger C Br J Haematol. 2019; 185(2):297-310.

PMID: 30768680 PMC: 6594003. DOI: 10.1111/bjh.15790.


Atypical hemolytic uremic syndrome and eculizumab therapy in children.

Kim S, Kim H, Kim S Korean J Pediatr. 2018; 61(2):37-42.

PMID: 29563942 PMC: 5854840. DOI: 10.3345/kjp.2018.61.2.37.


References
1.
Loirat C, Macher M, Elmaleh-Berges M, Kwon T, Deschenes G, Goodship T . Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant. 2010; 25(10):3421-5. DOI: 10.1093/ndt/gfq319. View

2.
Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M . Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol. 2013; 55(8):758-65. DOI: 10.1111/dmcn.12161. View

3.
Roumenina L, Jablonski M, Hue C, Blouin J, Dimitrov J, Dragon-Durey M . Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood. 2009; 114(13):2837-45. DOI: 10.1182/blood-2009-01-197640. View

4.
Sallee M, Daniel L, Piercecchi M, Jaubert D, Fremeaux-Bacchi V, Berland Y . Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010; 25(6):2028-32. DOI: 10.1093/ndt/gfq160. View

5.
Lin Z, Fukuda N, Jin X, Yao E, Ueno T, Endo M . Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2004; 44(1):42-7. DOI: 10.1161/01.HYP.0000129540.83284.ca. View